The investigated indices before and after treatment in sildenafil and placebo groups
| Parameters | Sildenafil | Placebo |
| 1 min heart rate recovery | ||
| Baseline (mean±SD) | 16±8.4 | 25.1±8.3 |
| After three months (mean±SD) | 19.2±9.9 | 22.8±9.8 |
| Change (median (IQR)) | −0.5 (−4.5 to 8.2) | −1 (−5.2 to 0.2) |
| P value | 0.84 | 0.2 |
| Maximum heart rate | ||
| Baseline (mean±SD) | 149±17.8 | 140.7±12.1 |
| After 3 months (mean±SD) | 161±11.2 | 140.1±10.7 |
| Change (median (IQR)) | 8.5 (0.7 to 26.2) | 1 (−11.0 to 8.0) |
| P value | 0.046 | 0.95 |
| Resting systolic blood pressure | ||
| Baseline (mean±SD) | 123.9±14.8 | 127.6±12.5 |
| After 3 months (mean±SD) | 111±10.8 | 117.6±15 |
| Change (median (IQR)) | −14.5 (−20.7 to −4.5) | −6.5 (−23.7 to 2.5) |
| P value | 0.005 | 0.083 |
| Resting diastolic blood pressure | ||
| Baseline (mean±SD) | 74.9±12.1 | 76.9±8.3 |
| After 3 months (mean±SD) | 70.6±7.1 | 78.9±7.1 |
| Change (median (IQR)) | −4.0 (−10.5 to 3.0) | 0 (−2.5 to 7.5) |
| P value | 0.11 | 0.50 |
| Corrected QT interval (ms) | ||
| Baseline (mean±SD) | 410.8±30.7 | 426.2±42.5 |
| After 3 months (mean±SD) | 389.8±38.3 | 429.2±34.7 |
| Change (median (IQR)) | −120 (−295 to 25) | 75 (−62.5 to 175) |
| P value | 0.058 | 0.44 |
| Functional capacity (METs) | ||
| Baseline (mean±SD) | 9.9±3.1 | 9.56±2.1 |
| After 3 months (mean±SD) | 13.1±3.3 | 9.63±2.4 |
| Change (median (IQR)) | 3.1 (1.1 to 4.1) | −0.5 (−1.9 to 2.4) |
| P value | 0.008 | 0.94 |
| Duke score | ||
| Baseline (median (IQR)) | 3.0 (0.0 to 9.0) | 7 (−1.5 to 9.25) |
| After 3 months (median (IQR)) | 9.5 (7.75 to 15) | 8 (1.5 to 11.25) |
| Change (median (IQR)) | 5.5 (1.0 to 9.2) | −0.5 (−2.0 to 4.2) |
| P value | 0.01 | 0.95 |
METs, metabolic equivalents.